Examining Socioeconomic and Computational Aspects of Vaccine Pharmacovigilance

الملخص EN

Background.

Vaccine pharmacovigilance relates to the detection of adverse events, their assessment, understanding, and prevention, and communication of their risk to the public.

These activities can be tedious and long lasting for regulatory authority scientists and may be affected by community practices and public health policies.

To better understand underlying challenges, we examined vaccine adverse event reports, assessed whether data-driven techniques can provide additional insight in safety characterization, and wondered on the impact of socioeconomic parameters.

Methods.

First, we integrated VAERS content with additional sources of drug and molecular data and examined reaction and outcome occurrence by using disproportionality metrics and enrichment analysis.

Second, we reviewed social and behavioral determinants that may affect vaccine pharmacovigilance aspects.

Results.

We describe our experience in processing more than 607000 vaccine adverse event reports and report on the challenges to integrate more than 95500 VAERS medication narratives with structured information about drugs and other therapeutics or supplements.

We found that only 12.6% of events were serious, while 8.97% referred to polypharmacy cases.

Exacerbation of serious clinical patient outcomes was observed in 8.88% VAERS cases in which drugs may interact with vaccinations or with each other, regardless of vaccine activity interference.

Furthermore, we characterized the symptoms reported in those cases and summarized reaction occurrence among vaccine-types.

Last, we examine socioeconomic parameters and cost-management features, explore adverse event reporting trends, and highlight perspectives relating to the use and development of digital services, especially in the context of personalized and collaborative health-care.

Conclusions.

This work provides an informative review of VAERS, identifies challenges and limitations in the processing of vaccine adverse event data, and calls for the better understanding of the socioeconomic landscape pertaining vaccine safety concerns.

We expect that adoption of computational techniques for integrated safety assessment and interpretation is key not only to pharmacovigilance practice but also to stakeholders from the entire healthcare system.